Early disturbances in multimodal evoked potentials as a prognostic factor for long-term disability in relapsing-remitting multiple sclerosis patients

被引:23
|
作者
London, Frederic [1 ]
El Sankari, Souraya [1 ]
van Pesch, Vincent [1 ]
机构
[1] Clin Univ St Luc, Dept Neurol, 10 Ave Hippocrate, B-1200 Brussels, Belgium
关键词
Multiple sclerosis; Multimodal evoked potentials; Predictive value; EDSS; Disability; PREDICT; PROGRESSION; ABNORMALITIES; DIAGNOSIS; MARKERS; MRI;
D O I
10.1016/j.clinph.2016.12.029
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: The aim of this study was to investigate whether early alterations in evoked potentials (EPs) have a prognostic value in relapsing-remitting multiple sclerosis (RRMS). Methods: We retrospectively selected 108 early MS patients with a neurological follow-up ranging from 5 to 15 years, in whom multimodal EPs (visual, brainstem auditory, somatosensory and motor) were performed at diagnosis. A conventional ordinal score was used to quantify the observed abnormalities. Results: The extent of change in the composite EP score was well correlated to the Expanded Disability Status Scale (EDSS) at ten years (Y-10) and up to 15 years (Y11-15) after disease onset. Analysis of the predictive value of the EP score showed an increased risk of disability progression at Y-10 and Y11-15 of 60% (p < 0.0001) and 73% (p < 0.0001) respectively in patients with an EP score > 4. Conversely, the risk of disability progression at Y-10 and Y11-15 associated with a lower EP score (64) was reduced to 16% and 20% respectively. Conclusions: Our data support the good predictive value for long-term disability progression of multimodal EPs performed early after disease onset in RRMS patients. Significance: This study, performed in a homogeneous RRMS cohort with long term follow-up, demonstrates the value of an early comprehensive neurophysiological assessment as a marker for future disability. (C) 2017 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:561 / 569
页数:9
相关论文
共 50 条
  • [41] Oxidative stress is associated with disability in relapsing-remitting multiple sclerosis patients
    Oliveira, S. R.
    Kallaur, A. P.
    Simao, A. N. C.
    Kaimen-Maciel, D. R.
    Lopes, J.
    Panis, C.
    Pereira, W. L. C. J.
    de Andrade, R. M.
    Reiche, E. M. V.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 343 - 343
  • [42] No evidence for CCVSI in relapsing-remitting multiple sclerosis patients with moderate disability
    Juenemann, Martin
    Yeniguen, Mesut
    Stolz, Erwin
    Berghoff, Martin
    [J]. JOURNAL OF NEUROLOGY, 2013, 260 (09) : 2409 - 2410
  • [43] Cognitive Impairment in Patients with Early Relapsing-Remitting Multiple Sclerosis
    Keklikoglu, Hava Doenmez
    Yoldas, Tahir Kurtulus
    Zengin, Oezkan
    Banu Solak, Elif
    Keskin, Selda
    [J]. NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2010, 47 (02): : 88 - 90
  • [44] Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis
    Cocco, E.
    Marchi, P.
    Sardu, C.
    Russo, P.
    Paolillo, A.
    Mascia, M. G.
    Solla, M.
    Frau, J.
    Lorefice, L.
    Massole, S.
    Floris, G.
    Marrosu, M. G.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (08) : 975 - 980
  • [45] The real life impact of early versus delayed treatment of interferon beta on long-term disability progression in relapsing-remitting multiple sclerosis
    Trojano, Maria
    Amato, Maria Pia
    Avolio, Carlo
    Bergamaschi, Roberto
    Cavalla, Paola
    Durelli, Luca
    Fuiani, Aurora
    Ghezzi, Angelo
    Lugaresi, Alessandra
    Lus, Giacomo
    Millefiorini, Enrico
    Paolicelli, Damiano
    Patti, Francesco
    Pellegrini, Fabio
    Imbaro, S. Maria
    Pozzilli, Carlo
    Rossi, Paolo
    Salemi, Giuseppe
    Vianello, Marica
    Livrea, Paolo
    Comi, Giancarlo
    [J]. NEUROLOGY, 2008, 70 (11) : A88 - A88
  • [46] Short-term prognosis in early relapsing-remitting multiple sclerosis
    Scott, TF
    Schramke, CJ
    Novero, J
    Chieffe, C
    [J]. NEUROLOGY, 2000, 55 (05) : 689 - 693
  • [47] Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis
    Zecca, C.
    Roth, S.
    Findling, O.
    Perriard, G.
    Bachmann, V.
    Pless, M. L.
    Baumann, A.
    Kamm, C. P.
    Lalive, P. H.
    Czaplinski, A.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 (05) : 762 - 767
  • [48] Long-term MRI observations of childhood-onset relapsing-remitting multiple sclerosis
    Balássy, C
    Bernert, G
    Wöber-Bingöl, C
    Csapó, B
    Kornek, B
    Széles, J
    Fleischmann, D
    Prayer, D
    [J]. NEUROPEDIATRICS, 2001, 32 (01) : 28 - 37
  • [49] Long-term effect of fingolimod on cardiovascular functioning in people with relapsing-remitting multiple sclerosis
    Haase, R.
    Forberger, C.
    Schilling, M.
    Piatkowski, F.
    Akgun, K.
    Rudiger, H.
    Ziemssen, T.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 609 - 610
  • [50] Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients
    Chan, Jillian K.
    de Lapiscina, Elena Hernandez Martinez
    Taylor, Carolyn
    Nguyen, Ai-Lan
    Alba-Arbalat, Salut
    Devonshire, Virginia
    Sayao, Ana-Luiza
    Carruthers, Robert
    Costello, Fiona
    Traboulsee, Anthony
    [J]. JOURNAL OF NEURO-OPHTHALMOLOGY, 2020, 40 (01) : 37 - 43